Mino 1999.

Methods	A patient report on methylphenidate‐induced psychosis in an adolescent with hyperkinetic disorder
Participants	Diagnosis of ADHD: DSM‐III‐R and later ICD‐10  (subtype: not stated) Age: 16 years old IQ: around 70 Sex: female Ethnicity: not stated Country: Japan Comorbidity: conduct disorder and secondary neurotic symptoms Comedication: not at the time when the patient took methylphenidate Sociodemographics: lives with parents and stepsister
Interventions	Methylphenidate type: not stated Methylphenidate dosage: 10 mg for 3 weeks, reduced to 5 mg for 1 week Administration schedule: once daily, morning Duration of intervention: 1 month Treatment compliance: not stated
Outcomes	Serious adverse events: 3 weeks after starting on methylphenidate (10 mg/day), the mother reported by telephone that the patient seemed depressed. Dose of methylphenidate was reduced to 5 mg/day. A week later the patient visited the clinic. The therapist diagnosed her condition as a depressive state and discontinued methylphenidate. 6 weeks after discontinuation of methylphenidate she was diagnosed with schizophrenic‐like psychotic state, due to symptoms of delusions of reference and persecution, delusional mood, silly smile and thought block. There was no evident hallucination. The patient took antipsychotic medication for 2 months, and her psychotic symptoms disappeared.
Notes	Key conclusions of the study authors: we discuss this case as an example of methylphenidate‐induced psychosis Comments from the study authors: we suggest that there are 2 types of methylphenidate psychosis: the first being hallucination dominant type and the second, delusion dominant type. This patient report address the second one Comments from the review authors: another article written in Japanese by the same authors found in our search. The abstracts of the 2 articles were identical, and the Japanese full‐text has therefore not been translated Funding/vested interests/authors' affiliations: not stated